Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis

Giorgio Seano1,2,3,9, Giulia Chiaverina1,2, Paolo Armando Gagliardi1,2, Laura di Blasio1,2, Alberto Puliafito1,2, Claire Bouvard4,5, Roberto Sessa1,2,8, Guido Tarone5, Lydia Sorokin6, Dominique Helley7, Rakesh K. Jain3, Guido Serini1,2, Federico Bussolino1,2 and Luca Primo1,2,9

The mechanism by which angiogenic endothelial cells break the physical barrier of the vascular basement membrane and consequently sprout to form new vessels in mature tissues is unclear. Here, we show that the angiogenic endothelium is characterized by the presence of functional podosome rosettes. These extracellular-matrix-degrading and adhesive structures are precursors of de novo branching points and represent a key feature in the formation of new blood vessels. VEGF-A stimulation induces the formation of endothelial podosome rosettes by upregulating integrin α6β1. In contrast, the binding of α6β1 integrin to the laminin of the vascular basement membrane impairs the formation of podosome rosettes by restricting α6β1 integrin to focal adhesions and hampering its translocation to podosomes. Using an ex vivo sprouting angiogenesis assay, transgenic and knockout mouse models and human tumour sample analysis, we provide evidence that endothelial podosome rosettes control blood vessel branching and are critical regulators of pathological angiogenesis.

Angiogenesis, the development of new vessels from pre-existing ones, plays a critical role in cancer progression. Endothelial cells (ECs), which lead this process, need to overcome several mechanisms attempting to keep the vascular network quiescent. To sprout and form new vessels, the first barrier that ECs have to cross is the vascular basement membrane (vBM), composed of laminins, collagen and proteoglycans.

Angiogenic factors, such as the well-studied vascular endothelial growth factor (VEGF), guide sprouting angiogenesis. When quiescent vessels sense angiogenic signals, tip ECs are stimulated to invade the underlying layer of vBM that prevents sprouting. This process requires proteolytic breakdown of selected vBM proteins that can be mediated by matrix metalloproteases (MMPs), such as membrane type-1 MMP (MT1-MMP; refs 5,6). However, the cellular mechanisms required for this process remain largely unknown.

Podosomes and invadopodia, collectively called invadosomes, are specialized cell–matrix contacts with an inherent ability to degrade extracellular matrix (ECM) in restricted areas and are typically characterized by enrichment in F-actin and cortactin7–9. They are considered key structures of cells that are able to cross anatomical boundaries, such as monocyte-derived cells and transformed fibroblasts7,10. Cultured ECs contain either isolated 1–μm-wide individual podosomes or 4–8-μm-wide ring-like clusters of podosomes, called podosome rosettes7,11,12. The appearance of individual podosomes and rosettes in ECs can be increased by soluble factors, such as TGF-β, or by phorbol esters11,12. Although endothelial podosome rosettes have been observed in TGF-β-stimulated aortic explants11, definitive in vivo evidence for their existence and a functional role for such structures is still lacking.

Here, we show that endothelial rosettes are critical regulators of sprouting angiogenesis and control tumour blood vessel branching. We demonstrate how the VEGF-induced upregulation of the α6 integrin subunit in ECs induces the formation of podosome rosettes and overcomes the vascular stabilizing and anti-angiogenic effects of the vBM laminin.

RESULTS
VEGF-A induces the assembly of podosome rosettes in ECs
Podosomes (identified by the co-localization of F-actin/cortactin at the basal side of ECs) were organized in two different
Figure 1. VEGF-A induces endothelial podosome rosettes. (a) a) Immunostained representative ECs treated with PMA for 30 min. Insets, zoom of the same representative ECs treated with PMA for 30 min. (b) ECs—incubated for 24 h in M199 10% FCS (unstimulated) or M199 10% FCS plus 30 ng ml⁻¹ of VEGF-A (24 h VEGF-A) were stained with phalloidin and then stained with phalloidin. The white dashed line is the outline of the cell boundary and is traced here as a guide to the eye. White arrows indicate the areas in which gelatin was degraded by individual podosomes or podosome rosettes. Scale bars, 10 µm. (c) Gelatin degradation assay by TIRF micrographs. ECs were seeded on FITC-conjugated gelatin, PMA-treated and then stained with phalloidin. The white dashed line is the outline of the cell boundary and is traced here as a guide to the eye. White arrows indicate the areas in which gelatin was degraded by individual podosomes or podosome rosettes. Scale bars, 10 µm. (d) Ex vivo VEGF-A stimulation induces podosome rosettes in aortic vessels. Aortic explants were incubated for 48 h in M199 10% FCS (unstimulated) or M199 10% FCS with 30 ng ml⁻¹ of VEGF-A (48 h VEGF-A). (e) Immunostaining of a representative 48 h VEGF-A-stimulated aortic explant. Inset, a podosome rosette. Scale bar, 20 µm. (f) Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test. (P<0.01 versus unstimulated).
compared with quiescent ECs (Fig. 1c). Moreover, larger areas of gelatin degradation—previously associated with podosomes13—were present in cells with podosome rosettes compared with individual podosomes (Fig. 1d).

To investigate whether endothelial podosome rosettes were present not only in cultured angiogenic ECs but also in vascular angiogenic endothelium, we analysed mouse aortic explants ex vivo-treated with VEGF-A for 48 h (Supplementary Fig. 1d). VEGF-A-stimulated aortae exhibited podosome rosettes, identified as circular F-actin- and cortactin-containing structures localized on the basal side of the endothelial layer (Fig. 1e and Supplementary Fig. 1d,e). In agreement with our in vitro observation, the number of cells with rosettes significantly increased in the endothelial layer of VEGF-A-stimulated aortae compared with unstimulated samples (Fig. 1f).

### Tumour angiogenic vessels are characterized by high levels of functional endothelial podosome rosettes

To investigate the presence of podosome rosettes in adult vessels undergoing in vivo angiogenesis, we analysed several tissues: two mouse models of tumour angiogenesis—the xenograft of B16F10 melanoma14 and the RipTag2 genetic model of pancreatic insulinoma6; a mouse model of post-ischaemic angiogenesis—the hindlimb ischaemia on gastrocnemius muscles15,16, and human clinical biopsies from lung tumours where high vascularity correlates with tumour progression20. In all tissues we were able to detect F-actin- and cortactin-positive ring-like structures in the EC membrane in close contact with vBM (Fig. 2a and Supplementary Fig. 2a–c). Notably, F-actin/cortactin rings were characterized by the absence or reduction of laminin staining in vBM (Fig. 2a and Supplementary Fig. 2a–c). This suggests that vBM components could be locally degraded. Indeed, in situ zymography21 on RipTag2 tumour slices revealed gelatinase activity in the regions that contained F-actin ring-like structures and were simultaneously devoid of laminin staining (Fig. 2b and Supplementary Fig. 2b,c,d). Podosome rosettes in tumour and ischaemic vessels had a mean diameter of (2.7 ± 0.7) μm (Fig. 2a and Supplementary Fig. 2a–c) and revealed the presence of podosomal markers, such as dynamin, phospho-FAK, phospho-cortactin and MT1-MMP (Supplementary Fig. 3a).

RipTag2 mice tumours are characterized by an angiogenic switch phase3,22. We visualized and quantified the number of endothelial podosome rosettes in tumour vasculature at different stages of tumour progression (Fig. 2c and Supplementary Fig. 3b). Whereas quiescent capillaries of normal islets were characterized by a negligible level of rosettes, the density of rosettes was strongly and significantly increased during the transition from the hyperplastic to the in situ tumour stage (Fig. 2c). Moreover, by measuring podosome rosettes in human lung tumour biopsies, we found that endothelial podosome rosette density is correlated with microvessel density and VEGF-A quantity (Fig. 2d,e and Supplementary Fig. 3c). Therefore, it seems that tumour angiogenic endothelium is characterized by a high number of ECM-degrading podosome rosettes.

### α6β1 integrin is essential for VEGF-induced endothelial podosome rosettes

Integrins are known to be involved in podosome formation17–25. Most of the integrins expressed in ECs were recruited in podosome rosettes of angiogenic ECs (Fig. 3a and Supplementary Fig. 4a). To investigate whether these integrins are functionally implicated in rosette formation, we treated angiogenic ECs with specific function blocking antibodies. The inhibition of α1β1, α3β1, α5β1, α6β1, or αvβ3, significantly impaired podosome rosette formation, suggesting a specific role for these integrins in rosette dynamics. Notably, only the α6β1 inhibition completely blocked the VEGF-induced rosette formation (Fig. 3a,b), impairing, in turn, MT1-MMP membrane localization and gelatin degradation (Fig. 3c and Supplementary Fig. 4b). Interestingly, individual podosomes were not affected by the anti-α6β1 treatment (Supplementary Fig. 4c). We confirmed the α6β1 involvement in rosette formation by silencing the α6 subunit (Supplementary Fig. 4d). Angiogenic ECs with reduced α6β1 integrin levels failed to form podosome rosettes (Fig. 3d). Furthermore, consistent with previous results16,27, VEGF stimulation strongly upregulated the expression of α6 integrin in ECs (Supplementary Fig. 4e), thus pointing to α6β1 as a potential effector acting downstream of VEGF in the signalling pathway that drives rosette formation.

Integrin α6β1 was gradually recruited in podosome rosettes during their formation (Supplementary Fig. 5a); we therefore speculated that α6β1 levels in endothelial podosome rosettes could correlate with their stability. To test this hypothesis, we analysed the lifespan of podosomes composing the rosettes in integrin α6–GFP (α6–GFP) and LifeAct–RFP-expressing ECs. Podosomes with high levels of integrin α6β1 exhibited significantly longer lifespans than podosomes with low α6β1 integrin (Fig. 3e and Supplementary Fig. 5b), confirming a crucial role for integrin α6 in the stability of podosomes in rosettes.

We then analysed α6 localization in VEGF-A-stimulated aortic explants. Integrin α6 co-localized with F-actin/cortactin ring-like structures in the basal side of the endothelial layer (Fig. 3f and Supplementary Fig. 5c), and lentiviral-mediated downregulation of α6 integrin in whole aortic explants significantly impaired rosette formation (Supplementary Fig. 5d). Moreover, experiments with aortic explants from Tie2-dependent integrin α6 null mice19 showed that genetic ablation of endothelial α6 completely suppressed the formation of endothelial rosettes (Fig. 3g).

### Laminin impairs endothelial podosome rosette formation

To gain insight into the function of α6β1 integrin in rosette formation, we investigated the role of laminin, the main α6β1 ligand26. Unexpectedly, plating ECs on laminin severely inhibited VEGF-A-induced rosette formation and strongly decreased the level of active MT1-MMP (Fig. 4a,b), but did not reduce the number of individual podosomes (Supplementary Fig. 6a). On the basis of these observations, we expected that laminin ablation from vBM could increase the number of podosome rosettes in blood vessels. To directly test this hypothesis, we stimulated with VEGF-A aortic explants isolated from Tie2-dependent integrin α6-RFP-expressing ECs. Podosomes with high levels of integrin α6RFP co-localized with F-actin/cortactin ring-like structures in the basal side of the endothelial layer (Fig. 4c and Supplementary Fig. 6b). Therefore, we evaluated whether the level...
Figure 2 Tumour angiogenic vessels are characterized by high levels of endothelial podosome rosettes. (a) Confocal imaging stacks of representative vessels in subcutaneous B16F10 melanoma, in angiogenic islets of transgenic RipTag2 mice or human samples of lung tumours. xyz-section of immunostaining for primary antibodies as indicated. Vessels are delimited by dashed lines; arrows indicate podosome rosettes. Inset, the podosome rosette. Schematization and 3D rendering in Supplementary Fig. 2a,b. Scale bars, 10 μm. (b) In situ zymography in RipTag2 angiogenic islets. xyz-section of staining for primary antibodies as indicated and gelatin-DQ (dye-quenched), showing the degraded gelatin. Vessels are delimited by white dashed lines; white arrows indicate podosome rosettes. Inset, the podosome rosette. 3D rendering in Supplementary Fig. 2e. Scale bar, 10 μm. (c) Graph shows the density of podosome rosettes in vessels of RipTag2 tumour mouse stages. Vessel regions of interest were determined with laminin staining. Mean ± s.e.m. of n = 3 mice, 5 fields per tumour stage. Statistical significance was calculated using a one-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (**P < 0.01 versus normal islets; ***P < 0.001 versus normal islets). (d) Scatter plots of the density of endothelial podosome rosettes versus microvessel density (MVD)-CD31 (r² = 0.49, P = 0.016) and VEGF area fraction in biopsy samples of lung tumours (r² = 0.46, P = 0.021). Mean ± s.e.m. of n = 3 different vessels per biopsy for rosette density and n = 20 fields per slide for MVD and VEGF. Statistical significance was calculated using a Pearson correlation test. Representative images are shown in Supplementary Fig. 3c.
Figure 3 Integrin α₆ is essential for VEGF-induced endothelial podosome rosette formation and function. (a) Table of integrin recruitment in endothelial podosome rosettes and functional blocking treatment. The qualitative analysis of rosette blockade is based on podosome-rosette-positive cells percentages in comparison with aspecific IgG treatment. Confocal micrographs of integrin recruitment are shown in Supplementary Fig. 4a. (b) Graph showing the percentages of podosome-rosette-positive ECs, stimulated as indicated and treated with aspecific IgG or anti-integrin blocking antibodies 2 h before PMA treatment. ECs were treated with IgG or anti-integrin blocking antibody (20 μg ml⁻¹) during cell adhesion and then stimulated with PMA for 30 min. Mean ± s.e.m. of n = 3 independent experiments in which 250 cells were analysed per experimental point. Statistical significance was calculated using a one-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (**P < 0.01 versus Unstim SCRL shRNA; ***P < 0.01 versus SCRL shRNA). (c) Cytofluorimetric analysis of active MT1-MMP in VEGF-A-stimulated ECs, treated with rat IgG or anti-α₆ blocking antibody and then stimulated with PMA for 30 min. Normalized mean ± s.e.m. of n = 3 independent experiments in which 9 x 10⁴ cells were analysed per experimental point. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (**P < 0.01 versus rat IgG). (d) Graph showing the percentages of podosome-rosette-positive ECs, transduced with scramble (SCRL) shRNA or shRNA against integrin α₆ (ITGA6 shRNA4 and ITGA6 shRNA5). Membrane integrin α₆ levels in transduced ECs are shown in Supplementary Fig. 4d. Mean ± s.e.m. of n = 3 independent experiments in which 250 cells were analysed per experimental point. Statistical significance was calculated using a one-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (**P < 0.01 versus Unstim SCRL shRNA; ***P < 0.01 versus SCRL shRNA). (e) Lifespan of the podosomes that form endothelial rosettes in α₆–GFP- and LifeAct–RFP-transduced ECs. Graph shows the lifespan in minutes of podosomes with low or high levels of integrin α₆ detected with TIRF microscopy (90 nm of depth) in VEGF-stimulated ECs. Mean ± s.e.m. of n = 230 podosomes from 3 different cells. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (***P < 0.001 versus low ITGA6). (f) Endothelial layer of a 48 h VEGF-A-stimulated aortic explant immunostained by the indicated antibodies and nuclear-stained by DAPI (blue). Inset, a podosome rosette in the basal side of the endothelial layer. Scale bar, 20 μm. (g) VEGF-A stimulation in aortic explants of Tie2–dependent α₆ null mice. Aortic explants from WT (α₆+/fl-Tie2Cre–) or endothelial α₆ null (α₆/fl-Tie2Cre+) mice were incubated for 48 h in M199 10% FCS (unstim) or M199 10% FCS with 30 ng ml⁻¹ of VEGF-A (48 h VEGF-A). Mean ± s.e.m. of n = 3 independent experiments in which 1,250 nuclei were analysed per experimental point. Statistical significance was calculated using two-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (***P < 0.001 versus unstim α₆/fl-Tie2Cre–; **P < 0.01 versus 48 h VEGF-A α₆/fl-Tie2Cre–).
Figure 4 Laminin impairs podosome rosette formation. (a) Graph showing the percentages of podosome-rosette-positive ECs, stimulated as indicated, seeded on gelatin-coated coverslips with the indicated addition of laminin. Percentages of individual-podosome-positive cells are in Supplementary Fig. 6a. Mean ± s.e.m. of n = 3 independent experiments in which 260 cells were analysed per experimental point. Statistical significance was calculated using a two-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\(P < 0.01\) versus unstimulated; \(P < 0.05\) versus LN (0 μg ml\(^{-1}\)); \(P < 0.01\) versus LN (0 μg ml\(^{-1}\))). (b) Cytofluorimetric analysis of active MT1-MMP in VEGF-stimulated ECs, seeded on a gelatin coating with the indicated addition of laminin. Normalized mean ± s.e.m. of n = 3 independent experiments in which 10\(^3\) cells were analysed per experimental point. Statistical significance was calculated using a two-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\(P < 0.05\) versus LN (0 μg ml\(^{-1}\)); \(P < 0.01\) versus LN (0 μg ml\(^{-1}\))). (c) VEGF-A stimulation in aortic explants of laminin null mice. Aortic explants from laminin \(\alpha_6\)-null or laminin \(\alpha_6\)-null mice were incubated for 48 h in M199 10% FCS (unstim) or M199 10% FCS with 30 ng ml\(^{-1}\) of VEGF-A (48 h VEGF-A). Mean ± s.e.m. of n = 3 independent experiments in which 550 nuclei were analysed per experimental point. Statistical significance was calculated using a two-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\(P < 0.05\) versus unstimulated laminin \(\alpha_6\)-null; \(P < 0.05\) versus 48 h VEGF-A laminin \(\alpha_6\)-null). (d) Integrin \(\alpha_6\) membrane localization is modulated by laminin in the substratum. The graph shows the ratio of \(\alpha_6\)-GFP fluorescence in the membrane (TIRF microscopy with <90 nm of deepness) and in the whole cell (epifluorescence, EPI) in the indicated periods of PMA treatment; mean ± s.e.m. of n = 30 cells from 3 independent experiments.

Supplementary Video 3). After PMA treatment, roughly all FAs disassembled and only a few focal complexes were still visible; then the formation of podosome rosettes became detectable (Fig. 5a and Supplementary Video 3). These results suggest that FA and podosome rosette dynamics are indeed correlated phenomena. Therefore, we studied rosettes in ECs treated with drugs able to modulate FA dynamics. First, we examined whether—as previously suggested\(^{29}\)—the formation of podosome rosettes is independent of direct \textit{de novo} protein synthesis, and we found that the protein-translation inhibitor cycloheximide did not interfere with the induction of rosettes (Fig. 5b). In contrast, the microtubule inhibitor nocodazole completely blocked the appearance of podosome rosettes. As nocodazole stabilizes FA and its ensuing removal results instead in FA disassembly\(^{30}\), we observed that nocodazole washout, besides favouring FA dismantling, significantly increased the formation of podosome rosettes on PMA treatment. Furthermore, challenging ECs with the recycling inhibitor primaquine extensively impaired the development of podosome rosettes (Fig. 5b) and completely blocked the stimulatory effect of nocodazole washout on rosette formation (Fig. 5b). These results support a model where FA components need to be trafficked to nascent podosome rosettes to allow the formation of the latter (Supplementary Fig. 6f).

The requirement for a PMA-elicted reorganization of ECM adhesions could explain why the binding of laminin to \(\alpha_6\beta_1\) integrin, which stabilizes this integrin in FAs, inhibits podosome rosettes. To confirm this hypothesis, we forced FA disassembly in ECs seeded on laminin. Microtubule-induced FA disassembly was sufficient to rescue the inhibitory effect of laminin on rosette formation (Fig. 5c), not affecting individual podosomes (Supplementary Fig. 6g). Taken together, these results suggest that the level of available \(\alpha_6\beta_1\) integrin is a limiting factor for endothelial podosome rosette formation. We therefore analysed rosette incidence in ECs with different levels of \(\alpha_6\beta_1\) integrin and seeded on different amounts of laminin. \(\alpha_6\)-silenced ECs failed to form rosettes independently of laminin concentration, whereas \(\alpha_6\beta_1\)-overexpressing ECs showed a high number of rosettes even when seeded on elevated concentrations of laminin (Fig. 5d). Conversely, modulation of \(\alpha_6\beta_1\) integrin levels did not affect individual podosomes (Supplementary Fig. 6h). Moreover, the overexpression of \(\alpha_6\) alone was sufficient to promote rosette formation in the absence of VEGF even in cells adhering on laminin (Fig. 5e).

**Endothelial podosome rosettes are precursors of new vessel branching points**

The presence of endothelial rosettes in the angiogenic endothelium prompted us to investigate their role in sprouting angiogenesis and vessel branching. We studied the formation of podosome rosettes in the mouse aortic ring (mAR) assay\(^{26,31}\). This \textit{ex vivo} angiogenesis model is characterized by the formation of VEGF-dependent capillary-like structures producing a vBM sleeve\(^{32}\) (Supplementary Fig. 7a). Ring-like structures with F-actin/cortactin/MT1-MMP colocalization were detectable in angiogenic sprouts. These ECM-degradative 4-μm-diameter structures were localized in the basal side of ECs (Fig. 6a,b and Supplementary Fig. 7b,c) and are also characterized by localization of integrin \(\alpha_6\) (Supplementary Fig. 7d). Interestingly, the levels of \(\alpha_6\) integrin on the surface of cells containing rosettes, but outside the rosette, were reduced compared with cells without rosettes (Supplementary Fig. 7e,f). This supports the hypothesis of a re-localization of \(\alpha_6\) from the cell surface to endothelial rosettes.

Notably, the localization of podosome rosettes in mAR sprouts was distal from the tip cell (Fig. 6b and Supplementary Video 4), suggesting that these structures were not necessarily involved in tip cell migration, but possibly in the process of branching from pre-existing sprouts. To validate this hypothesis, we performed live-imaging studies on podosome rosettes and lateral vessel branching.
**Figure 5** α6 integrin–laminin binding in FAs slows down α6 integrin translocation to podosome rosettes. (a) Time-lapse TIRF microscopy of vinculin–RFP-transfected ECs during PMA treatment. Insets, podosome rosettes indicated by arrows. For complete video, see Supplementary Video 3. Scale bar, 20 μm. (b) Graph showing the percentages of podosome-rosette-positive ECs, treated as indicated. CHX: cycloheximide; Noco: nocodazole; PQ: primaquine; NocoWO: nocodazole washout. Mean ± s.e.m. of n=3 independent experiments in which 200 cells were analysed per experimental point. Statistical significance was calculated using one-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\*P < 0.05 versus PMA treated; \*\*P < 0.001 versus PMA treated; \*\*\*P < 0.001 versus NocoWO+PMA). (c) Graph showing the percentages of podosome-rosette-positive ECs, seeded on gelatin-coated coverslips with the indicated addition of laminin. ECs were transfected as indicated. Membrane integrin α6 levels in transduced ECs are shown in Supplementary Fig. 4d. Percentages of individual-podosome-positive cells are in Supplementary Fig. 6g. Mean ± s.e.m. of n=3 independent experiments in which 320 cells were analysed per experimental point. Statistical significance was calculated using a two-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\*P < 0.05 versus no inhib LN (20 μg ml−1)). (d) Graph showing the percentages of podosome-rosette-positive ECs, seeded on gelatin-coated coverslips with 20 μg ml−1 laminin. ECs were transfected as indicated and stimulated or not with VEGF-A for 24 h. Mean ± s.e.m. of n=3 independent experiments in which 420 cells were analysed per experimental point. Statistical significance was calculated using an one-way ANOVA test followed by Bonferroni-adjusted post hoc t-tests (\*P < 0.05 versus its corresponding empty vector; \*\*P < 0.05 versus empty vector L-VEGF-A; \#P < 0.05 versus empty vector VEGF-A+).

**In vivo blocking of α6β1 integrin impairs endothelial podosome rosette formation and reduces tumour vessel branching**

To understand the physio-pathological relevance of endothelial podosome rosettes in the angiogenic process, we treated RipTag2 mice with the anti-α6 blocking antibody. We first tested the accessibility of anti-α6 to endothelial podosome rosettes\(^{36,34}\). Ten minutes after injection in RipTag2 mice, the anti-α6 antibody was sharply localized in podosome rosettes of tumour blood vessels (Fig. 7a and Supplementary Fig. 7i).

To evaluate the effects of anti-α6 on endothelial rosettes, we treated RipTag2 mice for 2 weeks by starting antibody administration at the beginning of the angiogenic stage. The blockade of α6β1 integrin caused a strong reduction of podosome rosette density (Fig. 7a) and concomitantly a decrease of vessel branching (Fig. 7c).

To confirm the results obtained with anti-α6 treatment, we analysed rosette density in vessels of B16F10 xenograft and ischaemic tissues from endothelial α6 integrin null mice. Genetic endothelial...
endothelial podosome rosettes precede vessel branching from a pre-existing vessel. (a) Confocal image stacks of representative angiogenic outgrowths from 7-day mARs into collagen gel (left panel). Scale bar, 50 μm. Right panel, xyz-section of the white dotted square in the left panel. Scale bar, 10 μm. (b) 3D isosurface rendering of endothelial rosettes in angiogenic outgrowths. Angiogenic outgrowths (grey) and podosome-rosettes (red) were recognized with co-localization of F-actin/cortactin staining (indicated by red arrows) as detailed in the Supplementary Methods. The white asterisk indicates the tip-cell nucleus. Inset, a representative endothelial rosette. For complete video, see Supplementary Video 4. Scale bar, 30 μm. (c,d) Time-lapse multiphoton microscopy of angiogenic outgrowths from LifeAct–EGFP mARs. For complete video, see Supplementary Videos 5 and 6. The podosome rosette and cell protrusion are indicated by white arrows. Scale bar, 20 μm in c and 50 μm in d.

Ablation of α6 integrin effectively impaired podosome rosettes in both models (Fig. 7d,e). B16F10 tumours showed that α6 integrin ablation significantly reduced blood vessel branching in tumours (Fig. 7f), confirming our ex vivo results (Fig. 6e). Notably, integrin α6 localized to podosome rosettes also in angiogenic vessels of human lung tumours (Supplementary Fig. 7l).

**DISCUSSION**

In the adult organism, blood vessels are usually quiescent and rarely form new branches. ECs and mural cells share a vBM that forms a sleeve around endothelial tubules and prevents resident ECs from leaving their positions. However, ECs are able to promptly respond to angiogenic signals. The mechanisms controlling vBM proteolytic breakdown and selection of the ECs that steer lateral branches are still poorly understood. Here, we show that angiogenic endothelium forms subcellular structures with degradative activity, called podosome rosettes, which precede the emergence of new lateral sprouts.

It is known that MMPs—including MT1-MMP—correlate with angiogenesis, by letting ECs breach the vBM and enter tissues. Spatial and temporal control of these proteinases is essential for an efficient sprouting. In angiogenic ECs podosome rosettes are plasma membrane regions where MT1-MMP is enriched. Indeed, it is reasonable that constrained degradation of vBM is preferable to diffuse and uncontrolled proteinase activity.

Furthermore, podosome rosettes are also adhesive structures containing integrins. Notably, in a model of BM invasion in *Caenorhabditis elegans*, the integrin heterodimer INA-1/PAT-3—highly homologous with mammalian α6β1—is crucial for cell invasion through BM (ref. 38). Here we show that the assembly of podosome...
In vivo blocking of integrin α6 impairs endothelial podosome rosette formation and reduces vessel branching in tumors. (a) Rapid accumulation of anti-α6 integrin antibody into endothelial podosome rosettes of RipTag2 tumour vessels. xyz-sections of confocal micrographs of the distribution of immunoreactivity in RipTag2 tumours 10 min after intravenous injection of 25 μg of anti-α6 integrin antibody. Vessels are delimited by white dotted lines; white arrows indicate the podosome rosette. Inset, high magnification of the podosome rosette. Scale bar, 5 μm. (b) Measurements of rosette density in vessels of RipTag2 mouse tumours, treated with rat IgG or anti-α6 blocking antibody. Mean ± s.e.m. of n = 30 fields, 5 fields per pancreatic islet from 6 mice per treatment group. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (P < 0.01 versus rat IgG). (c) Branching density in blocking anti-α6-treated RipTag2 tumours. Mean ± s.e.m. of n = 30 fields, 5 fields per mouse from 6 mice per treatment group. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (P < 0.05 versus rat IgG). (d) Measurements of rosette density in vessels of gastrocnemius muscles from unilateral hindlimb ischaemia experiments in WT (α6fl/fl-Tie2Cre−/−) or endothelial α6 null (α6fl/fl-Tie2Cre+/−) mice. Mean ± s.e.m. of n = 9 fields, 3 fields per muscle from 3 mice. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (P < 0.01 versus normal α6fl/fl-Tie2Cre−/−). (e) Measurements of rosette density in vessels of subcutaneous B16-F10 tumours in WT (α6fl/fl-Tie2Cre−/−) or endothelial α6 null (α6fl/fl-Tie2Cre+/−) mice. Mean ± s.e.m. of n = 32 fields, 3 fields per tumour from 7 mice per treatment group. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (P < 0.01 versus normal α6fl/fl-Tie2Cre−/−). (f) Branching density in B16F10 melanoma subcutaneously injected in Tie2-dependent α6 KO mice. Mean ± s.e.m. of n = 42 fields, 5 fields per tumour from 7 mice per treatment group. Statistical significance was calculated using an unpaired non-parametric Mann–Whitney test (P < 0.01 versus normal α6fl/fl-Tie2Cre−/−). (g) Cartoon showing α6 integrin/laminin molecular mechanisms involved in sprouting angiogenesis. (1) Quiescent EC have low levels of α6β1 integrin, which binds vBM laminin, is recruited in FAs, and results in blood vessel stabilization. (2) When the tumour produces VEGF, the VEGF induces up-regulation of the α6 integrin subunit in ECs. The increased availability of α6β1 integrin then allows the formation and stabilization of endothelial podosome rosettes and the ensuing MMP-driven degradation of ECM that, in turn, (3) allows vBM invasion by ECs and sprouting angiogenesis.
rosettes in ECs depends on $\alpha_\beta_1$ as well, thus supporting the idea that endothelial podosome rosettes are specialized structures for vBM invasion in vertebrates.

Whereas endothelial podosome rosettes are involved in the sprouting process of vessels embedded in a thick vBM, such as adult invasion in vertebrates. It that endothelial podosome rosettes are specialized structures for vBM development in embryos, but affects pathological angiogenesis in mature tissues.

Importantly, we demonstrated that VEGF-A stimulation induces the assembly of endothelial rosettes, but does not reduce the individual podosomes. This effect largely depends on $\alpha_\beta_1$ integrin, which is transcriptionally induced by VEGF-A. Recent evidence shows that both FAK and $\beta_1$ integrin are required for podosome rosette assembly and stabilization. However, the molecular mechanisms leading to the formation of podosome rosettes remain elusive. Here, we show that $\alpha_\beta_1$ contributes to the stability of podosome rosettes and that high levels of $\alpha_\beta_1$ are needed within podosome rosettes to increase their lifespans (Fig. 3e).

The transition from a quiescent to a migratory cellular phenotype is often characterized by FA disassembly followed by the formation of invadopodia or podosomes. Our data, showing that both disassembly of FAs and recycling of their components are necessary for rosette formation, unveil a direct link between FAs and rosettes (Supplementary Fig. 6f). In this context, laminin of vBM hampers rosette formation by sequestering $\alpha_\beta_1$ in FAs. The upregulation of $\alpha_\beta_1$—induced by angiogenic growth factor stimulation—could overcome the anti-angiogenic effect of vBM by increasing the $\alpha_\beta_1$ available for the formation of podosome rosettes, which in turn will allow vBM cleavage and angiogenesis.

The molecular actors that modulate adult vasculature geometry are poorly defined. The tortuosity and high branching index of tumour vasculature often make it ‘non-functional’, characterized by an impaired blood supply and interstitial hypertension, which compromise drug delivery. Notably, all angiogenic vessels that we analysed exhibited podosome rosettes but we could not detect them in quiescent vessels. This specific distribution suggests that endothelial podosome rosettes are determinants of angiogenic vessels. Indeed, we showed that inhibition of podosome rosette formation by $\alpha_\beta_1$ blockade or genetic deletion affects vessel branching (Fig. 6e and Fig. 7c,f). Consistently, previous evidence showed how inhibition or genetic ablation of $\alpha_\beta_1$ integrin in ECs impaired tumoral and post-ischaemic angiogenesis. In contrast, genetic ablation of laminin $\alpha_\beta_1$—described to give hyper-branched angiogenesis in the adult animal—promotes rosette formation and enhances endothelial sprouting. The control exerted by $\alpha_\beta_1$ integrin on tumour blood vessel branching as a consequence of podosome rosette inhibition in ECs supports the previously proposed notion of vascular normalization by suggesting endothelial podosome rosettes as a new target to normalize tumour vasculature.

In summary, this work describes the role of endothelial podosome rosettes as precursors of sprouting angiogenesis and important determinants of the vascular branching in tumour angiogenesis. We proposed a model (Fig. 7g) where quiescent vessels are characterized by low levels of $\alpha_\beta_1$ integrin, recruited in FAs and bound to the vBM laminin. This hampers the formation of podosome rosettes, reducing the sprouting ability. When a tumour persistently produces VEGF, $\alpha_\beta_1$ integrin is upregulated in ECs. The increased availability of $\alpha_\beta_1$ integrin allows the formation and stabilization of endothelial podosome rosettes and the ensuing MMP-driven modulation of ECM that, in turn, leads vBM invasion by ECs and sprouting angiogenesis.

METHODS

Methods and any associated references are available in the online version of the paper.

ACKNOWLEDGEMENTS

A special thank you to E. Georges-Labouesse (CNRS/INSERM/ULF I'llkirch, France), who recently passed away, for kindly providing Tie2-dependent integrin $\alpha_\beta_1$ KO mice. We thank P. C. Marchisio (San Raffaele Scientific Institute, Milano, Italy) and insightful suggestions on the manuscript; D. R. Sherwood (Duke University Medical Center, Durham, USA) for critical reading of the manuscript; K. Tryggvason (Karolinska Institutet, Stockholm, Sweden) for providing laminin $\alpha_\beta$ null mice; R. Wedlich-Soldner (Max-Planck Institute of Biochemistry, Martinsried, Germany) and L. M. Machesky (Beaton Institute for Cancer Research, Glasgow, UK) for providing breeding pairs for the LifeAct–EGFP mouse colony and reagents; R. Falcioni (National Cancer Institute ‘Regina Elena’, Rome, Italy) for critical reading of the manuscript; E. De Luca and M. Gai (MRC, Torino, Italy) for their assistance in multiphoton microscopy; Y. Boucher and C. Smith (HMS, Boston, USA) for assistance in immunohistochemistry on human tissues; and E. Giraudo and F. Maione (IRCC, Candiolo, Italy) for their help in the treatment of Rptf1tag mice. This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) investigator grants IG (10133, EB; 14635, LP; 13016 G. Serini) and fellowships (13604 G. Seano; 15026 P.A.G.); AIBC 5x1000 (12182); Converging Technologies Program, grant: ‘Photonic Biosensors for Early Cancer Diagnostics’; Technological Platforms for Biotechnology: grant DRUID; Fondazione Cassa di Risparmio Torino (FRT); Fondazione Piemontese per la Ricerca sul Cancro–ONLUS (Intramural Grant 5x1000 2008) (LP); Fondo Investimenti per la Ricerca di Base RBAP11BYNP (Newton) (F.B. and L.P.); University of Torino-Compagnia di San Paolo: RETHE grant (F.B.); GeneNet grant (L.P.); P01 CA080124/CA/NCI NIH HHS/United States (R.K.I.); The Fondazione T. & L. de Beaumont Bonelli and the Girardi Family (G. Seano).
METHODS

Cell culture and reagents. Human umbilical vein endothelial cells (ECs) were isolated from umbilical cord vein, characterized and grown as previously described[1]. In all experiments, ECs were used between passages two and five. To overcome the intrinsic biological variability of ECs, all data are shown as the mean of three independent experiments performed with a mix of ECs from three different umbilical cords.

293T (ATCC CRL-11268), B16F10 (ATCC CRL-6475) and HeLa (ATCC CCL-2) cell lines were obtained from the American Type Culture Collection and maintained as frozen stock. All experiments were performed on cell lines that had been passage for <6 months after thaw.

Rat monoclonal function-blocking antibody against integrin α6 (GoH3, MAB13501), specific rat IgG2a antibody, VEGF-A165 and FGF-2 were obtained from R&D Systems. Function-blocking antibody against α (FB12; MAB19732), α2 (BHA2.1; MAB19982), α3 (P1H4; MAB19632Z), α1 (P1D6; MAB19562Z) and αV (LM609; MAB19762) were obtained from Millipore. Each treatment was carried out with a final concentration of 20 µg ml−1 of azide-free antibody. Phorbol-12-myristate-13-acetate (PMA) was provided by Calbiochem. Laminin (Sigma) was isolated from Engelbreth-Holm-Swarm mouse sarcoma basement membrane. Nocodazole, primaquine, cycloheximide and porcine gelatin were obtained from Sigma-Aldrich.

In vitro podosome analysis. Subconfluent ECs were cultured with M199 10% FCS for 24 h and kept with or without 30 ng ml−1 VEGF-A for 24 h. ECs were then trypsinized and allowed to adhere for 2 h in M199 20% FCS on glass coverslips, previously coated with 1% porcine gelatin for 1 h. Cells were starved with serum-free M199 for 1 h and then stimulated for 5–60 min with 10% FCS M199 plus 80 ng ml−1 of PMA. To visualize podosomes, cells were paraformaldehyde (PFA)-fixed—4% PFA in PBS—and stained with anti-cortactin antibody (4F11, 05-180, Millipore) and phalloidin. We imaged ECs using a confocal laser-scanning microscope (TCS SP5 AOB; Leica) equipped with a ×63/1.30 HCX Plan-Apochromat oil-immersion objective. Podosome-roseate-positive cells were identified by co-localization of cortactin and F-actin in a ring-like structure. Individual-podosome-positive cells were characterized by co-localization of cortactin and F-actin in a dot-like distribution. All manual quantifications were performed in a double-blind manner.

Plasmid preparation. Lentivectors carrying short hairpin RNA (shRNA) sequences against human integrin α6 or a scramble sequence (used as control) were purchased from the RNAi Consortium library (Sigma-Aldrich). For lentivectors carrying GFP-tagged integrin α6 (α6-GFP) and LifeAct–RubyFP (LifeAct–RFP), we used the In-Fusion 2.0 CF Dry-Down PCR Cloning Kit (Clonetics). Integrin α6, cloned into the pWPXL lentiviral vector (Tronolab, http://tronolab.epfl.ch), was tagged with GFP inserted in the C-terminus. LifeAct–RubyFP (ref. 14) was provided by R. Wedlich-Soldner, Max Planck Institute of Biochemistry, Martinsried, Germany, and was inserted in the pLKO.1 lentiviral vector in the place of the puromycin resistance gene.

Lentiviral preparation, purification and concentration. Lentiviruses were produced by calcium phosphate transfection of vector plasmids—pCMVdR8.74 and envelope (pMD2.G-VSVG) plasmids in 293T cells. Supernatant produced by calcium phosphate transfection of vector plasmids—pLKO.1 shRNAs lentiviruses were provided by R. Wedlich-Soldner, Max Planck Institute of Biochemistry, Martinsried, Germany. For lentivectors carrying GFP-tagged integrin α6, GFP-infected ECs on gelatin-coated dishes, with or without laminin (final concentration 20 µg ml−1) for 3 h. After 30 min with M199 10% FCS with or without PMA treatment (80 ng ml−1), cells were trypsinized and samples were acquired with a CyAn ADP flow cytometer (Dako Cytomation) and data were analysed with Summit 4.3 software (Dako).

In vitro transfection and infection. ECs were transfected with pTagRFP–vinculin (FP372, Evrogen) by Lipofectamine Plus (Invitrogen) with pTagRFP–vinculin (FP372, Evrogen) by Lipofectamine Plus (Invitrogen) with pools of specific anti-integrin blocking antibodies were performed during a 2-hour-adhesion process in M199 20% FCS. Each treatment was carried out with a final concentration of 20 µg ml−1 of azide-free antibody.

Cytofluorimetric analysis. ECs were trypsinized and then incubated with PBS 1% BSA plus 5 µg ml−1 of mouse anti-integrin α6 monoclonal antibody (4F10; sc-53536, Santa Cruz Biotechnology), active MTI-MMP monoclonal antibody (3G4-2; MAB1767; Millipore) or mouse IgG for 30 min at 4 °C. After three washes with PBS 1% BSA, cells were incubated with 2.5 µg ml−1 of Alexa 488-conjugated anti-mouse antibody (Invitrogen) for 30 min. After final rinses with PBS, samples were analysed with a CyAn ADP flow cytometer (Dako Cytomation) and data were analysed with Summit 4.3 software (Dako).

Integrin α6–GFP expression analysis in ECs. We seeded integrin α6–GFP-infected ECs on gelatin-coated dishes, with or without laminin (final concentration 20 µg ml−1) for 3 h. After 30 min with M199 10% FCS with or without PMA treatment (80 ng ml−1), cells were trypsinized and samples were acquired with a CyAn ADP flow cytometer (Dako Cytomation) and data were analysed with Summit 4.3 software (Dako).

RipTag2, endothelial ITGA6 KO and Lamata−/− mice. Generation of RipTag2 mice as a model of pancreatic islet cell carcinogenesis has been previously reported [16]. RipTag2 mice were maintained in the C57Bl/6j background (Jackson Laboratory). From 12 weeks of age, all RipTag2 mice received 50% sugar food (Harlan Teklad) and 5% sugar water to relieve hypoglycaemia induced by the insulin-secreting tumours. LifeAct–EGFP mice were generated previously [17], and provided by R. Wedlich-Soldner (Max-Planck Institute of Biochemistry, Martinsried, Germany) and L. M. Machesy (Beatson Institute for Cancer Research, Glasgow, UK). Mice were housed under the approval and the institutional guidelines governing the care of laboratory mice of the University of Turin Committee on Animal Research and in compliance with the international laws and policies.

Generation of α6 floxed mice (α6fl/fl-Tie2Cre+) has been reported previously [18]. For mouse breeding, both combinations were used: α6fl/fl-Tie2Cre+ (KO) male with α6fl/fl-Tie2Cre− (WT) female or α6fl/fl-Tie2Cre− (WT) male with α6fl/fl-Tie2Cre+ (KO) female. Integrin α6 KO female mice were fertile and we did not observe any evident differences during pregnancy or in newborn number or size, as described in ref. 19. All protocols were approved by the Regional Ethics Committee on Animal Experimentation (PZ.CBV/031.07, CEEA34.CB.041.11 and CEEA34.CB.011.11) and all experiments complied with Directive 2010/63/EU of the European Parliament.

Lamata−/− mice were generated previously [20,21]. Melanoma tumour subcutaneous injection. One million B16F10 melanoma cells were suspended in 100 µl of PBS and injected subcutaneously into the right flank of 8-week-old α6fl/fl-Tie2Cre+ and α6fl/fl-Tie2Cre− male mice. Twelve days later the mice were anaesthetized with a single intraperitoneal injection of ketamine (80 mg kg−1) and xylazine (16 mg kg−1), then killed by cervical dislocation. Tumours were collected and frozen in isopentane solution cooled in liquid nitrogen before being stored at −80 °C until immunohistological analysis.

Unilateral hindlimb ischaemia. The hindlimb ischaemia experiment was performed as previously described [22,23]. Male mice aged 7–8 weeks were anaesthetized with a single intraperitoneal injection of ketamine (80 mg kg−1) and xylazine (16 mg kg−1) and were separated from the femoral nerve, ligated, and excised from proximal to the superficial epigastric artery to proximal to the bifurcation of the saphena and popliteal arteries. On day 14 after ischaemia induction, ischaemic and non-ischaemic gastrocnemius muscles were collected and

© 2014 Macmillan Publishers Limited. All rights reserved.
frozen slowly in isopentane solution cooled in liquid nitrogen, before being stored at −80 °C.

Human lung tumour data. Endothelial podosome rosette levels, microvessel density (MVD) and area fraction of F-actin (FAF-A) were determined in the lung sections of a cohort of patients collected between 1992 and 1993 before surgical resections with the approval of the Massachusetts General Hospital Institutional Review Board and previously analysed in ref. 49. The Massachusetts General Hospital Institutional Review Board determined that our investigation did not meet the definition of‘human subjects research’. We did not obtain data through an intervention or interaction with individual subjects or identifiable private information about living individuals. The patients had a variety of pre- and post-surgical treatments and tumour stages. We analysed 11 biopsies, 3 vessels per tumour for rosette quantification and 20 different regions of interest (ROIs) per biopsy for MVD and VEGF.

Immunostaining. ECs plated on coated glass cover slips, whole-mount mouse aortic explants, whole-mount mARs or 30–50 μm cryosections of mice tumours were equivulated in PBS, PAF-fixed and permeabilized with PBS 0.3% Triton X-100. For biopsy, samples from human patients, 10-μm-formalin-fixed paraffin-embedded (FFPE) sections were de-waxed and permeabilized with PBS 0.3% Triton X-100. Primary antibodies—mouse anti-cortactin (1:100, 4F11; 05-180; Millipore), rabbit anti-paxillin (1:100, Y131; 04-581; Millipore), goat anti-MT1-MMP (1:100, 4G4, MAB1767; Millipore), rabbit anti-MT1-MMP (1:150, AB35712, Abcam), mouse anti-dynamin (1:100, E-11; sc-74532, Santa Cruz Biotechnology), rabbit anti-phospho-cortactin (1:100, Tyr 421; AB3852; Millipore), mouse anti-phospho-FAK (1:80, Tyr 397; ABT135; Cetac), mouse anti-vinculin (1:1,000, kV1N-1; V3191; Sigma-Aldrich), mouse anti-αβ3, integrin (1:100, FB12; MAB1973; Millipore), mouse anti-αβ5, integrin (1:100, BHA2.1; MAB1998; Millipore), mouse αv integrin (1:100, P185; MAB1952; Millipore), mouse anti-αβ5 integrin (1:100, P4C2; MAB1955; Millipore), mouse anti-αv, integrin (1:50, P1ID6; MAB1956; Millipore), mouse anti-αvβ6, integrin (1:100, LM609; MAB1976; Millipore), rat anti-αv, integrin (1:50, GoH3; MAB13501; R&D System), mouse anti-β3, integrin (1:100, 450-11, a gift from R. Falcioni, National Cancer Institute ‘Regina Elena’, Rome, Italy), and rabbit anti-laminin (1:80, AB2034, Millipore)—were diluted in PBS 5% donkey serum and incubated overnight at 4 °C in a humidified chamber. Cover slips or specimens were washed with PBS and incubated for 30 min at room temperature with secondary antibodies and counterstained with Alexa488-conjugated phallolidin (Invitrogen) and 4,6-diamidino-2-phenylindole (DAPI). Cover slips or specimens were analysed using a confocal laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×63/1.30 HCX Plan-Asphomat oil-immersion objective. Confocal stack images were digitally post-processed with blind deconvolution algorithms.

Endothelial podosome density in tumours. We stained tumour slices with anti-laminin (1:80, AB2034, Millipore) and anti-cortactin (4F11, 05-180, Millipore) antibody and phalloidin and performed confocal imaging with a laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×40/0.95 HCX Plan-Asphomat oil-immersion objective. After three-dimensional (3D) blind deconvolution algorithms, tumour vessel volumes were recognized by using laminin staining using Imaris 6.3 software (Bitplane, AG). To count endothelial podosome rosettes, several discriminating criteria were followed: endothelial podosome rosettes were identified as ring-like structures within vessels with co-staining for F-actin and cortactin, close to a region depleted in laminin staining, and with a diameter ranging between 2 and 6 μm. All manual quantifications were performed in a double-blind manner.

In situ zymography. Tissue sections (RipTag2 or human lung tumours) or whole-mount mARs were fixed in acetone and immunostained as indicated. Substrate for in situ zymography was prepared by diluting DQ gelatin (0.1% in deionized H2O, Invitrogen) 1:50 in a reaction buffer containing PBS 5 mM CaCl2. Tissue sections or whole-mount mARs were incubated in a dark humidity chamber at 37 °C in gelatin solution for 2 h. Samples were then carefully rinsed with PBS and PFA-fixed for 10 min in the dark. To verify the contribution of metalloproteinases, control slides were pre-incubated with 20 μM EDTA or protease inhibitor mix (leupeptin, aprotinin and pepstatin) for 1 h. Specimens and whole-mount mARs were analysed using a confocal laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×40/0.95 or ×63/1.30 HCX Plan-Asphomat oil-immersion objective. Confocal stack images were digitally post-processed with deconvolution algorithms.

Immunohistochemistry on human tissue. FFPE sections (5 μm thick) were immunostained following the manufacturer’s recommendations and standard protocols with antibodies against the following antigens: mouse anti-human CD31 (JC70A; 102870; Dako) and mouse anti-human VEGF (Ab-7; MS1-1467-P0; Thermo Scientific). Sections were visualized by the avidin–biotin complex immunoperoxidase method, observed with a bright-field microscope and photographed. MVD and VEGF-positive area were estimated in 20 ROIs of the tumour on CD31- or VEGF-stained sections using a customized analysis with ImageJ (NIH).

Intravenous injection of antibody and detection. Rapid accessibility of antibody was analysed as previously described50,51. 25 μg of anti-αβ3 (GoH3, R&D) or nonspecific IgG, diluted to 125 μl final volume with 0.9% NaCl, were injected through the tail vein. Antibodies were allowed to circulate for 10 min and the tissues were fixed by vascular perfusion. The chest was opened rapidly; and the vasculature perfused for 3 min with PFA fixative from a cannula inserted into the aorta through an incision in the left ventricle. The right atrium was incised to provide an exit for the fixative. After the perfusion, tissues were removed, stored and obtained as OCT-embedded sections. The localization of antibodies was detected by incubating sections with Alexa-647 goat anti-rat antibody, phallolidin and anti-cortactin antibody. Confocal stack images were post-processed with blind deconvolution algorithms with Autodeblur (Media Cybernetics) and ImageJ (NIH).

Therapeutic antibody treatment. The therapeutic antibody treatment was performed in RipTag2 mice as previously described51. In brief, the dosage regimen used was 0.125 mg of anti-αβ3, integrin antibody (GoH3, R&D) per mouse through tail vein injection. Antibody treatment started when mice reached the age of 9 weeks and continued for 15 days. Control animals were treated with purified rat IgG2A (25 μg/mouse) at a dose of 0.125 mg per mouse every 2 days for 2 weeks. Cohorts of 6 mice were treated for each arm of the trial study.

Vascular branching index in tumours. The vessel branching index (also ‘vessel branching incidence’) is the number of manually counted branching points/vascular volume and is independent of the vascularization rate. We stained tumour slices with anti-laminin (1:80, AB2034, Millipore) or anti-CD31 (JC70A; 102870; Dako) antibody and analysed them using a confocal laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×20/1.40 HCX Plan-Asphomat oil-immersion objective. After maximum projection of 30-μm-slices, we manually counted branching points and divided them by a given vessel volume as described above. All manual quantifications were performed in a double-blind manner.

Ex vivo podosome stimulation in aortic explants. Aortas were explanted as previously described52. After isolation from fibro-adipose tissue, aortae were cut along their long axis and then sectioned in 1 mm2 squares and then incubated for 24 h in serum-free medium with antibiotics. Aortic segments were incubated for 48 h in M199 10% FCS plus antibiotics with or without 30 ng ml−1 of VEGF-A. In the case of knockdown experiments media were supplied with Polybrene and lentiviral supernatants.

To visualize podosome-positive cells, we PFA-fixed aortic explants and stained them with anti-cortactin (4F11, 05-180, Millipore) antibody and phallolidin and imaged them using a confocal laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×40/0.95 HCX Plan-Asphomat oil-immersion objective. After 3D blind deconvolution algorithms (ImageJ plugins), podosome-positive cells in the endothelial layer were recognized by identifying regions of co-localization of cortactin and F-actin in ring-like structures in the endothelial layer. The endothelial layer was easily identified as ECs are not as highly stained by phallolidin as smooth muscle cells (SMCs); the endothelial layer and the SMC layer are divided by a highly autofluorescing layer of elastin; moreover, the circularity of nuclei allowed to distinguish ECs from SMCs because endothelial nuclei are circular and not elongated53. These criteria were previously described52 and are summarized in Supplementary Fig. 1d. All manual quantifications were performed in a double-blind manner.

Mouse aortic ring angiogenesis assay. The mouse aortic ring (mAR) assay was performed as previously described54–57 with the following modifications. After explant, mARs were incubated for 2 days in serum-free medium. Aortic explants were then kept in place on glass-bottom dishes (Wilico, Intracr) with a drop of 20 μl of type-1 collagen gel (from rat tail, Roche) and covered with Endothelial Basal Medium (EBM, Clonetics) 5% FCS with VEGF-A (20 ng/ml, R&D) and FGF-2 (10 ng/ml−1, R&D).

Time-lapse analysis of mAR model. LifeAct–EGFP, endothelial αv null and Lama4−/− mARs were embedded in type-1 collagen gel, stimulated as described previously and kept at 37 °C in a 5% CO2 humidified atmosphere for 24–72 h on glass-bottom dishes.

LifeAct–EGFP, endothelial αv null or Lama4−/− mARs were imaged with a ×20/0.75 dry objective (Leica Microsystems) with an inverted photomicroscope (DM IRB HC; Leica Microsystems) in phase-contrast or epifluorescence.
Methods

LifeAct-EGFP mARs were imaged with a x20/0.50 dry objective (Leica Microsystems) with a multiphoton microscope Leica TCSII SP5. Z stacks were acquired at 512 x 512 resolution, scan speed of 400 Hz, and 1 µm z-step size.

To investigate the relation between endothelial podosome rosettes and lateral sprouting, we analysed 8 lateral protrusion events from 3 different mARs. We measured the time of persistence and diameter of ring-like structures. Data obtained in LifeAct-GFP mARs were corroborated by the quantification of rosettes in fixed confocal sections of mARs identified by co-staining of cortactin (4F11, 05-180, Millipore) and F-actin. Rates of rosettes per unit length and time were calculated by knowing the duration of rosettes and assuming a uniform density over every branch of the mAR. Lateral sprouting in mARs was instead quantified in live bright-field movies, where we identified protrusions emerging from pre-existing branches and either retracting or developing into full secondary branches.

Integrin α6 membrane localization in mARs. After 10 days of culture, live mARs were treated with the rat anti-antibody GoH3 (0.2 µg/ml-1 MAB13501; R&D System) for 1 h and then PFA-fixed. The localization of the anti-α6 antibody (GoH3) was detected by whole-mount incubation with Alexa-647-conjugated goat anti-rat antibody, anti-cortactin (4F11, 05-180, Millipore) antibody, phallolidin and DAPI. We quantified the anti-α6 antibody in cells with or without endothelial rosettes by using phallolidin and DAPI staining to distinguish the cell edges and phallolidin and cortactin for podosome rosettes (shown in Supplementary Fig. 7e). Confocal stacks of images were quantified using ImageJ (NIH).

Image analysis. Immunostained cryosections or mouse tumours or whole-mounted mARs were imaged using a confocal laser-scanning microscope (TCS SP5 AOBS; Leica) equipped with a ×40/0.95 (z-step = 0.4 µm) or ×63/1.30 HCX Plan-Apochromat oil-immersion objective (z-step = 0.3 µm). To increase the signal to noise ratio, confocal images were obtained by using a high line average and a low scan speed.

To reduce optical distortions, images were filtered with blind deconvolution algorithms by means of Autodelir (Media Cybernetics). We applied 5 iterations for light microscopy, 10 for confocal stacks, and 3 for multiphoton 4D analysis. Podosome rosettes were identified in deconvoluted stacks and checked, a posteriori, in each raw stack.

For ease of visualization, we reconstructed the 3D geometry of confocal stacks by isosurface rendering using Imaris 6.3 (Bitplane, AG). Briefly, each channel was binarized with a threshold level chosen automatically by the software.

Fluorescence image quantification. Fluorescence intensity quantification was performed using Leica Confocal Software (Leica), ImageJ (NIH) or Imaris 6.3 (Bitplane, AG). Image acquisition was performed maintaining the same laser power, gain and offset settings. In the case of in vitro experiments, we analysed 10 different cells for each experimental point, in three independent experiments. Integrin α6 localization in podosome rosettes was detected as mean fluorescence in podosome ROIs. Podosome ROIs were manually selected by using co-localization of cortactin and phallolidin staining.

In the case of vBM fluorescence quantification in proximity of endothelial podosome rosettes, we analysed 5 different fields for each mouse. After 3D blind deconvolution algorithms, tumour vessel volumes were recognized by using isosurface of vBM staining. vBM was detected as laminin staining. Volumes of vBM were subdivided in 1,000-µm³-volumes. The volumes of vBM were then classified in vBM volumes with or without endothelial rosettes. Mean fluorescence of laminin staining in vessel volumes was quantified by Imaris 6.3 (Bitplane, AG).

Statistical analysis. No statistical method was used to predetermine sample size, but the sample size was conceived to obtain a 95% confidence level and a confidence interval of 5%, which were verified a posteriori once the experiment was performed. For cells and aortic explants, we used the experiments in Fig. 1 to set the maximum (VEGF-A stimulation) and the minimum (unstimulated) for the following experiments. The animal numbers for anti-α6 treatments and for integrin α6 null mice experiments are based on similar experiments in the past. The investigators were not blinded during the treatments, but they were blinded for all image analyses and manual quantifications. The experiments were not randomized.

Data are presented as means ± standard error (s.e.m.) of three independent experiments. For in vitro assays, each experiment was performed with a mix of ECs from three different umbilical cords. For digital quantification of fluorescence in specific ROIs, we measured 6 fields per experimental point in three independent experiments. For in vivo studies, cohorts of 6 mice were treated for each arm of the anti-α6 antibody treatment study in RipTag2 mice, cohorts of 7 mice were analysed for each arm of the B16F10 tumours in α6 null mice and cohorts of 3 mice for ischaemic treatments in α6 null mice. For human sample analysis, we studied 11 biopsies, three different vessels per biopsy and the measurement of 20 ROIs per slide for MVD and VEGF.

Prism (GraphPad Software) was used for analysis. Statistical analyses were performed using unpaired t-tests or, when more than two groups were assessed, by ANOVA followed by Bonferroni-adjusted post hoc t-tests. F-tests were used to determine whether groups had equal variance; if equality was not established unpaired t-tests with Welch's correction were performed. A D'Astigno–Pearson test was used to assess normality. A Mann–Whitney test was used when normality was not achieved. A Pearson test was used for correlation analyses in human tissues because all three sets (rosette densities, MVD and VEGF areas) passed the normality test. Statistical significance was achieved when P was less than 0.05.

For representative images, we repeated the experiments multiple times: Fig. 1a (10 cells), Fig. 1d (5 cells), Fig. 1e (5 aortic explants), Fig. 2a (5 fields per mouse in 3 mice, 3 fields per biopsy for a total of 33 images), Fig. 2b (2 fields per mouse in 3 mice), Fig. 3f (6 aortic explants), Fig. 5a (5 different cells), Fig. 6a (3 mARs), Fig. 6b (3 mARs), Fig. 6c (4 sprouts), Fig. 6d (8 lateral sprouts), Fig. 6a (2 fields per mouse in 3 mice). Supplementary Fig. 1a (5 cells per podosomal marker), Supplementary Fig. 1c (5 cells), Supplementary Fig. 1e (5 aortic explants), Supplementary Fig. 2a (5 fields), Supplementary Fig. 2c (9 fields), Supplementary Fig. 2e (2 fields), Supplementary Fig. 2f (3 fields in 2 different biopsies), Supplementary Fig. 3a (5 fields per mouse in 3 mice, 3 fields per biopsy for a total of 33 images), Supplementary Fig. 3b (2 fields), Supplementary Fig. 3c (20 fields per slide for MVD and VEGF), Supplementary Fig. 4a (at least 3 cells per marker), Supplementary Fig. 5b (2 cells), Supplementary Fig. 5c (6 aortic explants), Supplementary Fig. 6e (3 cells), Supplementary Fig. 7a (2 mARs), Supplementary Fig. 7b (2 mARs), Supplementary Fig. 7c (3 mARs), Supplementary Fig. 7c (3 mARs), Supplementary Fig. 7e (12 fields), Supplementary Fig. 7f (2 mARs), Supplementary Fig. 7i (2 fields in 2 different mice), Supplementary Fig. 7j (2 fields in 2 different biopsies).

Supplementary Figure 1  Endothelial podosome rosettes in cultured EC and aortic explants. (a-b) Immunostained representative VEGF-A-stimulated EC treated with PMA for 30 min. Scale bar: 10 µm. (c) Cytofluorimetric analysis of membrane MT1-MMP localization, EC treated with PMA for the indicated time. Normalized mean ± SEM of n = 3 independent experiments in which 8×10^4 cells were analyzed per experimental point. (**, P < 0.01 versus T=0.) Statistical significance was calculated using paired nonparametric Wilcoxon test. (d) Schematic representation of mouse aortic explant microanatomy. Endothelial cells (EC) are characterized by large round nuclei and vascular smooth muscle cells (SMC) by thin and elongated nuclei. Along the z-axis, the two cell types were seen separated by the top elastic lamina. Yellow dotted line, schematization of the z plane of microscopic analysis of endothelial rosettes. (e) Immunostaining of a representative 48 h VEGF-A-stimulated aortic explant. In yellow, 3D reconstruction of the co-localization channel in podosome rosette. Individual channel images from Fig. 1e. Scale bar: 20 µm.
Supplementary Figure 2 3D rendering of endothelial podosome rosettes in RipTag2 tumour and ischaemic vessels. (a) Schematic representation of endothelial tumoural rosettes detection. Endothelial cells (EC) are delimited by red line while vBM is colored in magenta, in green there is the schematization of endothelial tumoural rosettes visualized as shown in Fig. 2a. Yellow arrows indicate the rosettes. (b) 3D reconstruction of a representative endothelial rosette in RipTag2 tumours. Isosurface of vBM — detected as laminin staining — was coloured in red, endothelial rosettes — F-actin/cortactin co-localization — in yellow and nuclear staining in blue. Scale bar: 5 µm. (c) Confocal imaging stacks of representative vessels in hindlimb ischaemia experiment on gastrocnemius muscles. Xyz-section of immunostaining for primary Abs as indicated. Vessels are delimited by white dotted lines; white arrows indicate podosome-rosettes. Scale bar: 10 µm. (d) vBM quantification in different regions of tumour vessels in RipTag2 tumours. vBM was detected as laminin staining. vBM volumes were subdivided in 1000-µm³-volumes. Therefore, the sub-volumes of vBM were classified in vBM volumes without endothelial rosettes (no rosette vBM volumes) and vBM volumes with endothelial rosettes (rosette vBM volumes). Normalized mean ± SEM of n = 420 subvolumes of vBM from 5 fields per mouse for a total of 3 mice per treatment group. (***, P < 0.001 versus no rosette vBM volumes.) Statistical significance was calculated using unpaired nonparametric Mann-Whitney test. (e) 3D reconstruction of in situ zymography in a representative endothelial rosette of RipTag2 tumours. After deconvolution, isosurface of vBM — detected as laminin staining — was coloured in magenta, F-actin in red and Gelatin-DQ — indication of gelatin degradation — in green. Scale bar: 10 µm. (f) In situ zymography in lung tumours from patients. Staining for primary Abs as indicated and Gelatin-DQ (dye-quenched), i.e. degraded gelatin. Vessel is delimited by white dotted lines; white arrows indicate podosome-rosettes. Scale bar: 10 µm.
Supplementary Figure 3  Endothelial podosome markers and endothelial density in tumours vessels. (a) Confocal images of representative vessels in angiogenic islets of RipTag2 mice. Xyz-section of immunostaining for primary Abs as indicated and nuclear-stained by DAPI (blue). Vessels are delimited by white dotted lines; white arrows indicate podosome-rosettes. Scale bar: 3 µm. (b) 3D isosurface rendering of tumour vessels in a 12-µm-thick slice of a representative RipTag2 angiogenic islet. Vessels (gray) detected with laminin staining and podosome-rosettes (red) recognized with co-localization of F-actin/cortactin staining. Red arrows indicate podosome-rosettes. Tickmarks on axis: 10 µm. (c) Representative micrograph images of CD31 and VEGF staining in biopsy samples of lung tumours. Scale bar: 50 µm. Quantifications and correlations in Fig. 2d.
Supplementary Figure 4 Integrin recruitment in endothelial podosome rosettes. (a) Confocal images of representative VEGF-stimulated EC, PMA-treated for 30 min. Inset, of the podosome-rosettes. Scale bar: 20 µm. (b) Gelatin degradation assay on EC treated with rat IgG or anti-α6 blocking Ab after 1 hour of stimulation with PMA. Mean ± SEM of n = 10 cells from 3 independent experiments (***, P < 0.001 versus Rat IgG). Statistical significance was calculated using unpaired nonparametric Mann-Whitney test. (c) Graph shows the percentages of individual podosome positive EC, stimulated as indicated and treated with rat IgG or anti-α6 blocking Ab. Mean ± SEM of n = 3 independent experiments in which 250 total cells were analyzed cells per experimental point. (d) Cytofluorimetric analysis of membrane integrin α6 localization. EC were transduced with shRNA scramble (SCRL shRNA) or against integrin α6 (ITGA6 shRNA4 and shRNA5). Mean ± SEM of n = 3 independent experiments (***, P < 0.001 versus shSCRL). Statistical significance was calculated using one-way ANOVA test followed by Bonferroni adjusted post-hoc t-tests. (e) Cytofluorimetric analysis of membrane integrin α6 localization. EC were incubated for 24 h in M199 10% FCS (unstimulated) or in M199 10% FCS plus 30 ng/ml of VEGF-A (24 h VEGF-A) or for 48 h in M199 10% FCS plus 30 ng/ml of VEGF-A (48 h VEGF-A). Mean ± SEM of n = 3 independent experiments. (**, P < 0.01 versus unstimulated; ***, P < 0.001.) Statistical significance was calculated using one-way ANOVA test followed by Bonferroni adjusted post-hoc t-tests.
Supplementary Figure 5 Integrin α6 recruitment in endothelial podosomes and integrin α6 silencing in aortic explants. (a) Integrin α6 fluorescence quantification in rosettes regions. Rosettes regions were manually selected using co-localization of cortactin and F-actin staining. Mean ± SEM of n = 3 independent experiments in which 30 total cells were analyzed cells per experimental point. (***, P < 0.001 versus T=0). Statistical significance was calculated using paired nonparametric Wilcoxon test. (b) TIRF microscopy of LifeAct-RFP (red) and α6-GFP (green) localization in EC treated with PMA for 15 min. EC were seeded on gelatin-coated glass-bottom dishes. The complete sequence of time-lapse TIRF microscopy is shown in Supplementary Video 2. Scale bar: 20 µm. Zoom of white dotted square is shown in the lower panels. Scale bar: 1 µm. (c) Endothelial layer of a 48 h VEGF-A-stimulated aortic explant from Fig. 3f. In yellow, 3D reconstruction of the co-localization channel in podosome rosette. Scale bar: 20 µm. (d) Aortic explants were incubated for 48 hours in M199 10% FCS (unstimulated) or M199 10% FCS with 30 ng/ml of VEGF-A (48 h VEGF-A) plus lentiviruses carrying scramble shRNA (SCRL shRNA) and shRNA targeting murine ITGA6 (shRNA48 and shRNA50). Graph shows the percentage (%) of podosome-rosettes positive in the endothelial layer of aortic explants, treated and transduced as indicated. Mean ± SEM of n = 3 independent experiments in which 340 total nuclei were analyzed cells per experimental point. (**, P < 0.01 versus unstimulated; *, P < 0.05 versus SCRL shRNA; ***, P < 0.01 versus SCRL shRNA.) Statistical significance was calculated using one-way ANOVA test followed by Bonferroni adjusted post-hoc t-tests.
Supplementary Figure 6 Laminin effects on individual podosomes. (a) Graph shows the percentages of individual podosome positive EC, stimulated as indicated and seeded on gelatin coated-coverslips with addition of laminin. Percentages of podosome-rosette positive cells in Fig. 4a. Mean ± SEM of n = 3 independent experiments in which 260 total cells were analyzed cells per experimental point. (b) Integrin α6 fluorescence quantification in rosettes regions of VEGF-A-stimulated EC. Rosettes ROI were manually selected using the co-localization of cortactin and F-actin staining. Normalized mean ± SEM of n = 3 independent experiments in which 30 cells were quantified per experimental point. (**, P < 0.01 versus LN=0.) Statistical significance was calculated using one-way ANOVA test followed by Bonferroni adjusted post-hoc t-tests. (c-d) Degradation of α6-GFP in PMA-treated EC on laminin. Cyttofluorimetric analysis of GFP fluorescence in α6-GFP-transduced EC. EC stimulated as indicated and seeded on gelatin coated-plates with indicated addition of laminin. Mean ± SEM of n = 3 independent experiments in which 105 cells were analyzed per experimental point. (e) Confocal image of a representative VEGF-stimulated EC seeded on glass-bottom dishes coated with gelatin plus 20 μg/ml of laminin for 2 hours. Inset, of focal adhesion. Scale bar: 20 μm. (f) Schematic representation of trafficking model accordingly data shown in Fig. 5a,b. Disassembly of focal adhesions (FA) allows to recruit structural components that are recycled in newly-formed rosettes. Nocodazole (Noco) blocks FA disassembly, primaquine (PQ) blocks integrin recycling, while de novo synthesis blocked by cicloheximide (CHS) does not modulate endothelial rosette formation. (g) Graph shows the percentages of podosome-rosettes positive EC, seeded on gelatin-coated with indicated laminin addition and PMA-treated with or without nocodazole washout. Percentages of podosome-rosette positive cells in Fig. 5C. Mean ± SEM of n = 3 independent experiments in which 230 cells were analyzed per experimental point. No statistical significance in the modulation of individual podosome was seen. (h) Graph shows the percentages of podosome-rosettes positive EC, seeded on gelatin coated-coverslips with indicated addition of laminin. EC were stable-transduced as indicated. Membrane integrin α6 levels in transduced EC are shown in Supplementary Fig. 4d. Percentages of individual-podosome positive cells in Fig. 5d. Mean ± SEM of n = 3 independent experiments in which 420 total cells were analyzed cells per experimental point. No statistical significance in the modulation of individual podosome was seen.
Supplementary Figure 7 Endothelial podosome rosettes in mAR and tumours. (a) Self-produced vBM layer – detected as laminin staining – in mAR model. Confocal images of immunostainings for primary Abs as indicated. Scale bar: 5 µm. (b) High-magnification confocal images of immunostaining for MT1-MMP in 7-day mAR model. White arrows indicate podosome-rosettes. Scale bar: 5 µm. (c) In situ zymography in 7-day mAR. Staining for primary Abs as indicated and gelatin-DQ (dye-quenched), i.e. degraded gelatin. White arrows indicate podosome-rosettes. Scale bar: 3 µm. (d) Rapid accumulation of anti-α6 integrin Ab into focal adhesions and podosome rosettes of mAR detected by secondary anti-rat antibody. Immunostaining with primary Abs as indicated. Scale bar: white arrows indicate 10 µm. Podosome-rosettes. (e) Quantification of the localization in membrane of anti-α6 integrin Ab. Normalized mean ± SEM of n = 12 regions of interest (ROI), 4 ROI per mAR for a total of 3 mAR per experimental point. (*, P < 0.05 versus w/o rosette.) Statistical significance was calculated using unpaired nonparametric Mann-Whitney test. (right panel) Schematic representation of the selection of ROIs in panel B. Phalloidin and DAPI stains were used to distinguish the cell edges and phalloidin and cortactin for podosome rosettes. Scale bar: 10 µm. (f) Characterization of LifeAct-EGFP mAR endothelial rosettes. Confocal images of immunostainings for primary Abs as indicated. Scale bar: 5 µm. (g) Sprout length quantification of capillary-like structures from endothelial α6 null mAR (α6fl/fl-Tie2Cre+). Normalized mean ± SEM of n = 16 mAR, 4 mAR per mouse from a total of 4 mice. No significant modulation of sprout length was seen. (h) Sprout length quantification of capillary-like structures from Laminin α4 KO mAR (Lama4−/−). Normalized mean ± SEM of n = 8 mAR, 2 mAR per mouse from a total of 4 mice. No significant modulation of sprout length was seen. (i) Confocal micrographs of the distribution of immunoreactivity to GoH3 in Riptag2 tumours 10 min after i.v. injection of 25 µg of anti-α6 integrin antibody detected by secondary anti-rat antibody. Immunostaining with primary Abs as indicated. Scale bar: 5 µm. Vessel is delimited by white dotted lines as a guide to the eye; podosome-rosette is indicated by white arrow. Inset, of podosome-rosette. Scale bar: 10 µm.
Supplementary video legends

Supplementary Video 1 – Actin dynamics in endothelial podosome rosettes formation. Time-lapse microscopy of LifeAct-RFP localization in EC treated with PMA for the indicated time. Pseudocolors: TIRF in green and EPI in red. EC were seeded on gelatin-coated glass-bottom dishes. Scale bar: 10 µm.

Supplementary Video 2 – Integrin α6 dynamics in adhesive structures during PMA treatment in EC seeded on laminin-rich substrates or not. Time-lapse TIRF microscopy of LifeAct-RFP (red) and α6-GFP (green) localization in EC treated with PMA for the indicated time. EC were seeded on glass-bottom dishes coated with gelatin plus laminin at indicated concentrations. Scale bar: 15 µm.

Supplementary Video 3 – Focal adhesions and podosome rosettes dynamics during PMA treatment. Time-lapse TIRF microscopy of vinculin-RFP (black) localization in EC. EC were cultured in basal medium and then treated with basal medium plus PMA at the indicated time. EC were seeded on gelatin-coated glass-bottom dishes. Scale bar: 20 µm.

Supplementary Video 4 – 3D reconstruction of endothelial podosome rosettes in angiogenic outgrowths. 3D reconstruction of angiogenic outgrowth from mAR into collagen gel. mAR were stimulated with VEGF-A and FGF-2 for 7 days, then fixed and immunostained. Isosurface of F-actin staining was coloured in gray and endothelial rosettes – co-localization of cortactin and F-actin – in red.

Supplementary Video 5 – Endothelial podosome rosettes in angiogenic outgrowth from LifeAct-EGFP mAR. Xyz-section of time-lapse 2-photon microscopy of angiogenic outgrowths from LifeAct-EGFP mAR, stimulated with VEGF-A and FGF-2. In the video the formation of a 5-6 µm-diameter rosette is evident, followed by a cell protrusion of 14-16 µm of length. Top-left panel is the x-plane, top-right is the z-plane, bottom-left is the y-plane and bottom-right is the image. Scale bar: 20 µm.

Supplementary Video 6 – Branching from endothelial rosettes in LifeAct-EGFP mAR. Time-lapse 2-photon microscopy of angiogenic outgrowths from LifeAct-EGFP mAR, stimulated with VEGF-A and FGF-2. Inset, 3D reconstruction of endothelial podosome rosette of the same video. Scale bar: 50 µm.

Supplementary Video 7 – Dynamical analysis of vessel branching in endothelial ITGA6 KO mAR. Time-lapse phase-contrast microscopy of angiogenic outgrowths from mAR. mAR from WT (α6fl/fl-Tie2Cre-) or endothelial α6 KO (α6fl/fl-Tie2Cre+) mice were stimulated with VEGF-A and FGF-2. Scale bar: 70 µm.

Supplementary Video 8 – Dynamical analysis of vessel branching in Lama4-/- KO mAR. Time-lapse phase-contrast microscopy of angiogenic outgrowths from mAR. mAR from WT or Laminin α4 null (LAMA4 mAR) mice were stimulated with VEGF-A and FGF-2. Scale bar: 70 µm.

Supplementary Video 9 - Dynamical analysis of vessel branching in mAR into laminin-rich matrices. Time-lapse phase-contrast microscopy of angiogenic outgrowths from mAR into type-I-collagen gel with or without 20 µg/ml of laminin addition. mARs were stimulated with VEGF-A and FGF-2. Scale bar: 70 µm.